NO20010651L - Inhibering av type 3 3<alfa>-hydroxysteroiddehydrogenase - Google Patents

Inhibering av type 3 3<alfa>-hydroxysteroiddehydrogenase

Info

Publication number
NO20010651L
NO20010651L NO20010651A NO20010651A NO20010651L NO 20010651 L NO20010651 L NO 20010651L NO 20010651 A NO20010651 A NO 20010651A NO 20010651 A NO20010651 A NO 20010651A NO 20010651 L NO20010651 L NO 20010651L
Authority
NO
Norway
Prior art keywords
type
hydroxysteroid dehydrogenase
inhibition
alpha
inhibitors
Prior art date
Application number
NO20010651A
Other languages
English (en)
Other versions
NO20010651D0 (no
Inventor
Fernand Labrie
Yves Merand
Sylvain Gauthier
Louis Provencher
Van Luu-The
Original Assignee
Endorech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endorech Inc filed Critical Endorech Inc
Publication of NO20010651D0 publication Critical patent/NO20010651D0/no
Publication of NO20010651L publication Critical patent/NO20010651L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

Det blir beskrevet nye metoder for behandling og/eller inhibering av utviklingen av prostatisk cancer, benign prostatisk hyperplasi, prostatitis, kviser, seboré, hirsutisme og androgenisk allopecia ved anvendelse av inhibitorer av type 3 3cc-hydroksysteriod dehydrogenase alene eller kombinasjon med andre aktive farmasøytiske midler slik som inhibitor av type 5 17(3-hydroksysteroid dehydrogenase. Det blir også beskrevet nye inhibitorer og farmasøytiske produkter.
NO20010651A 1998-08-07 2001-02-07 Inhibering av type 3 3<alfa>-hydroxysteroiddehydrogenase NO20010651L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9562398P 1998-08-07 1998-08-07
PCT/CA1999/000724 WO2000007576A2 (en) 1998-08-07 1999-08-06 INHIBITORS OF TYPE 3 3α-HYDROSTEROID DEHYDROGENASE

Publications (2)

Publication Number Publication Date
NO20010651D0 NO20010651D0 (no) 2001-02-07
NO20010651L true NO20010651L (no) 2001-04-05

Family

ID=22252842

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20010651A NO20010651L (no) 1998-08-07 2001-02-07 Inhibering av type 3 3<alfa>-hydroxysteroiddehydrogenase

Country Status (9)

Country Link
EP (1) EP1102582A2 (no)
JP (1) JP2002522380A (no)
CN (1) CN1322130A (no)
AR (1) AR021757A1 (no)
AU (1) AU5144999A (no)
CA (1) CA2339368A1 (no)
ID (1) ID28791A (no)
NO (1) NO20010651L (no)
WO (1) WO2000007576A2 (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5504074A (en) 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
US6908910B2 (en) 1993-08-06 2005-06-21 The Children's Medical Center Corporation Estrogenic compounds as anti-mitotic agents
EP1321146A3 (en) * 1998-03-11 2004-06-02 Endorecherche Inc. Inhibitors of type 5 and 3 17beta-hydroxysteroid dehydrogenase and methods for their use
US7087592B1 (en) 1999-08-23 2006-08-08 Entre Med, Inc. Compositions comprising purified 2-methoxyestradiol and methods of producing same
US6891953B1 (en) 2000-06-27 2005-05-10 Microsoft Corporation Method and system for binding enhanced software features to a persona
US7135581B2 (en) 2000-08-18 2006-11-14 Entremed, Inc. Antiangiogenic agents
US6995278B2 (en) 2000-08-18 2006-02-07 Entre Med, Inc. Antiangiogenic agents
CA2430100A1 (en) * 2000-11-27 2002-05-30 Entremed, Inc. Antiangiogenic agents
US6710037B2 (en) * 2001-05-01 2004-03-23 Schering Corporation Method of treating androgen-dependent disorders
DE60239207D1 (de) * 2001-08-10 2011-03-31 Takeda Pharmaceutical Gnrh-agonistische kombinationsmittel
EP1666033B1 (en) * 2001-11-29 2008-12-31 GTX, Inc. Prevention and treatment of androgen-deprivation induced osteoporosis
US7524866B2 (en) 2001-11-29 2009-04-28 Gtx, Inc. Prevention and treatment of androgen—deprivation induced osteoporosis
JP2007529426A (ja) 2004-03-12 2007-10-25 エントレメッド インコーポレイテッド 抗血管新生薬
DE102004032674A1 (de) * 2004-07-02 2006-01-26 Schering Ag Neue 2-substituierte Estra-1,3,5(10)-trien-17-one als Inhibitoren der 17β-Hydroxysteroiddehydrogenase Typ 1
US7419972B2 (en) 2004-07-02 2008-09-02 Schering Ag 2-substituted estra-1,3,5(10)-trien-17-ones as inhibitors of 17β-hydroxy steroid dehydrogenase type 1
CA2646065C (en) 2006-03-20 2014-01-14 Entremed, Inc. Disease modifying anti-arthritic activity of 2-methoxyestradiol
US9284345B2 (en) * 2007-04-12 2016-03-15 Endorecherche, Inc. 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators
EP2181990B1 (en) * 2007-08-31 2012-08-08 Astellas Pharma Inc. Piperidine derivative
CN101698834B (zh) * 2009-09-08 2012-05-23 北京利德曼生化股份有限公司 3α-羟基类固醇脱氢酶及其核苷酸序列、重组载体、重组宿主细胞和试剂盒
JP6196302B2 (ja) 2012-07-10 2017-09-13 バイエル・ファルマ・アクティエンゲゼルシャフト ３−置換エストラ−１，３，５（１０），１６−テトラエン誘導体、その調製法、これらを含む医薬製剤および医薬を調製するためのその使用
KR20150118153A (ko) * 2013-02-21 2015-10-21 바이엘 파마 악티엔게젤샤프트 17.베타.-히드록시스테로이드 데히드로게나제 (akr1 c3)의 억제를 위한 에스트라-1,3,5(10),16-테트라엔-3-카르복스아미드
CN104873525A (zh) * 2014-02-27 2015-09-02 天津药物研究院 一种11β-羟基类固醇脱氢酶抑制剂及其药用组合物和用途
CN104873520A (zh) * 2014-02-27 2015-09-02 天津药物研究院 一种11β-羟基类固醇脱氢酶抑制剂、药用组合物及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3562260A (en) * 1965-08-23 1971-02-09 Ormonoterapia Richter Spa 2-carbonyl-estratrienes and method of their preparation
US4340602A (en) * 1978-10-18 1982-07-20 Wayne State University Compositions inhibiting estrogen sulfotransferase activity
EP0117117A1 (en) * 1983-02-22 1984-08-29 Joachim Georg Liehr Improvements in or relating to the treatment of estrogen deficiency conditions
US4568673A (en) * 1984-03-20 1986-02-04 Wayne State University Compositions inhibiting murine MXT ductal carcinoma
US5504074A (en) * 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
CN1429104A (zh) * 1998-03-11 2003-07-09 内部研究股份有限公司 5型和3型17β－羟基类固醇脱氢酶的抑制剂及其用法

Also Published As

Publication number Publication date
AR021757A1 (es) 2002-08-07
WO2000007576A3 (en) 2000-03-30
EP1102582A2 (en) 2001-05-30
CA2339368A1 (en) 2000-02-17
WO2000007576A2 (en) 2000-02-17
NO20010651D0 (no) 2001-02-07
CN1322130A (zh) 2001-11-14
JP2002522380A (ja) 2002-07-23
AU5144999A (en) 2000-02-28
ID28791A (id) 2001-07-05

Similar Documents

Publication Publication Date Title
NO20010651L (no) Inhibering av type 3 3&lt;alfa&gt;-hydroxysteroiddehydrogenase
LV12316A (lv) 16-aizvietoti 4-azoandrostani ka 5-alfa-reduktazes izozima 1 inhibitori
BR9908592A (pt) Processo para inibir a atividade de 17ß-hidroxiesteróide desidrogenase tipo 5, composição farmacêutica, inibidor de 17ß-hidroxiesteróide desidrogenase tipo 5, processo para inibir 17ß-hidroxiesteróide desidrogenase tipo 3, inibidor de 17ß-hidroxiesteróide desidrogenase tipo 3, processos para tratar, ou reduzir o risco de desenvolver, câncer da próstata, hiperplasia prostática benigna, acne, seborréia, hirsutismo ou alopécia androgênica, sìndrome de ovário policìstico, câncer de mama, endometriose ou leiomioma, para inibir as secreções hormonais testiculares, para tratar puberdade precoce, e, kit
DE69329240D1 (de) 17-ether und thioether von 4-aza-steroiden
EA200000220A1 (ru) Сочетание ингибитора тирозинкиназы и химической стерилизации для лечения рака предстательной железы
DE69329149T2 (de) 4-azasteroide als 5-alpha-reduktase
TR200002224T2 (tr) Matris-bozucu metalloproteinasları inhibe eden sülfonilamino türevleri.
DE60309667D1 (de) Biphenylderivate und ihre verwendung als antiandrogene
HU9501411D0 (en) Pyran-2-one- and 5,6-dihydro-pyran-2-one derivatives for treating hiv- and other retrovirus infections
IS2012B (is) Kínólín og kínasólín efnasambönd nytsamleg í meðferð, einkum til að meðhöndla góðkynja vefjaauka í blöðruhálskirtli
EA200100571A1 (ru) Комбинированный способ лечебного воздействия, включающий применение лучевой терапии и ингибитора циклооксигеназы-2(cox-2) для лечения неоплазии
EP0646007A4 (no)
DE69326008D1 (de) 17-amino-substituierte 4-azasteroide als 5-alpha-reductase inhibitoren
DE69417925D1 (de) 7-substituierte-4-aza-steroid-derivate als 5-alpha-reductase-hemmer
MXPA03002495A (es) Proceso para preparacion de compuestos de n-(fenil sustituido)-3-alquil, aril- y heteroarilsulfonil-2-hidroxi-2-alquil- y haloalquilpropanamida.
DE69519728D1 (de) 17 beta-aryl-4-aza-steroidderivate
ATE451107T1 (de) 3-o-sulfamatsteroidderivate als hemmer von estronsulfatase
ES2182487T3 (es) Procedimiento para el tratamiento de agua en circulacion procedente de una instalacion de laqueado.
NO983724D0 (no) 17-&lt;beta&gt;-syklopropyl (amino/oksi)-4-aza-steroider som aktive inhibitorer av testosteron-5-&lt;alfa&gt;-reduktase og C17-20-lylase
DE69615046T2 (de) 17-alkyl-7-substituierte-4-aza-steroidderivate
NO974801D0 (no) Koldrengjöringspreparater basert på alkaner eller cykloalkaner og en organisk forbindelse omfattende en ketongruppe
TR200201167T2 (tr) Sodyum-hidrojen değiştirici tip 1 önleyici kristalleri.
YU12295A (sh) 16-supstituisani-4-aza-androstani inhibitori 5-alfa-reduktaze izozima 1
IT1238011B (it) Composizioni farmaceutiche a base di inibitori della riduttasi del hmg-coa per il trattamento della ipertrofia prostatica benigna.
UA33951A (uk) Вольфрамат 1,2,3-бензотриазолію як інгібітор малоциклового корозійно-втомного руйнування металів в нейтральних середовищах

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application